Objective To investigate the efficient care for the terminal malignant tumor therapy with CIK and bevacizumab,so as to reduce the adverse reactions and improve clinical outcomes.Methods A retrospective analysis on care methods and effects was conducted in 40 patients with terminal malignant tumor received CIK and bevacizumab chemotherapy.Results No patients was terminate therapy for serious adverse reactions of CIK and bevacizumab,and 3 cases of fever,2 cases of mild allergy,9 cases of hypertension,2 cases of urinary protein,5 cases of oral bleeding,1 case with scant hemoptysis,they were successfully finish the treatment plan after timely treated.Conclusions Appropriately formulating nursing interventions according to the treatment characteristics of CIK and bevacizumab can effectively prevent and mitigate the adverse reactions,and improve the efficacy.